Los Angeles, CA March 13th 2014 – Yesterday, the New York Times published an article citing our estimate of the U.S. molecular diagnostics (MDx) Human Papillomavirus (HPV) market at ~$200M (our internal estimate: $225M).Based on a couple of customer inquiries, we provide this brief blog entry to clarify the source and methodology that we used to generate this estimate.This figure was obtained from our proprietary MDx marketbook which estimates sales of >250 independent IVD tests from >50 companies participating in the MDx space. This data is published in the 5th edition of our MDx report.

Two triangulation points support this estimate:

• In a presentation entitled “Diagnostics and Personalized Healthcare, Roche independently estimated the U.S. MDx market at $250M
• In its fourth quarter and full 2013 results, Qiagen reported 2013 HPV sales of ~$210M (16% of 1,306.3M of 2013 adjusted net sales), including ~$130M in the U.S. (10% of sales). Our analysis suggests that Qiagen maintained an average ~65% market share (quickly declining throughout the year) in 2013. This would implicate a 2013 U.S. MDx HPV market size of ~$200M.

Please read our upcoming separate blog entry for implications of this announcement for key players in this space.

Author: Stephane Budel, Partner at DeciBio, LLCConnect with Stephane Budel on Google+https://plus.google.com/+StephaneBudel